This is Whytee's reference point.
In addition, as described in the 2018 FDA guidance document for clinical trial endpoints, time-to-event measures such as overall survival aredifficult to interpret in single-arm trials, and Study 001 was not designed to detect differences in survival. And therefore, survival endpoints will not be discussed further by FDA.
Can anyone see reference to now " irrelevant future long term survival data"
Whytee refuses to acknowledge he took the above information and fabricated a story to suit his narrative .
Perhaps JB1975 concocting that Si has just made up the potency assays also fits a certain narrative .
How absurd
Reg
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-467
-
- There are more pages in this discussion • 541 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.20 |
Change
-0.055(4.38%) |
Mkt cap ! $1.367B |
Open | High | Low | Value | Volume |
$1.22 | $1.23 | $1.20 | $2.924M | 2.422M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 157741 | $1.20 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.21 | 42049 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 157741 | 1.200 |
22 | 201473 | 1.195 |
17 | 170778 | 1.190 |
14 | 220739 | 1.185 |
16 | 560338 | 1.180 |
Price($) | Vol. | No. |
---|---|---|
1.205 | 42049 | 15 |
1.210 | 59617 | 15 |
1.215 | 74078 | 13 |
1.220 | 85489 | 10 |
1.225 | 121765 | 8 |
Last trade - 11.26am 25/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online